597 reports of this reaction
3.8% of all CRISABOROLE reports
#7 most reported adverse reaction
RASH is the #7 most commonly reported adverse reaction for CRISABOROLE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 597 FDA adverse event reports linking CRISABOROLE to RASH. This represents approximately 3.8% of all 15,699 adverse event reports for this drug.
Patients taking CRISABOROLE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among CRISABOROLE users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for CRISABOROLE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 597 FDA reports for CRISABOROLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.8% of all adverse event reports for CRISABOROLE, making it a notable side effect.
If you experience rash while taking CRISABOROLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.